8-K Announcements
6Material company update
Mar 17, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Nov 10, 2025·SEC
ArriVent BioPharma, Inc. Common Stock(AVBP)Earnings, Financials & Key Ratios
AVBP•NASDAQ
$29.62
$1.26B mkt cap·Price updated May 6, 2026
AboutArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Show more
- Revenue$0
- EBITDA$0+100.0%
- Net Income-$166M-106.6%
- EPS (Diluted)-4.32-68.8%
- ROE-58.88%-49.6%
- Debt/Equity0.00-93.3%
AVBP Key Insights
ArriVent BioPharma, Inc. Common Stock (AVBP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 88 (top 12%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 22.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AVBP Price & Volume
ArriVent BioPharma, Inc. Common Stock (AVBP) stock price & volume — 10-year historical chart
Loading chart...
AVBP Growth Metrics
ArriVent BioPharma, Inc. Common Stock (AVBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-106.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-80.75%
Return on Capital
10 Years-36.8%
5 Years-36.8%
3 Years-45.93%
Last Year-
AVBP Recent Earnings
ArriVent BioPharma, Inc. Common Stock (AVBP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (56%)
Q2 2026Latest
Mar 5, 2026EPS
$0.78
Est $0.87
+10.3%
Revenue
—
Q4 2025
Nov 10, 2025EPS
$0.83
Est $0.78
-6.4%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$0.90
Est $0.70
-28.6%
Revenue
—
Q2 2025
May 12, 2025EPS
$1.90
Est $0.66
-187.9%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.78vs $0.87+10.3% | — |
| Q4 2025 | Nov 10, 2025 | $0.83vs $0.78-6.4% | — |
| Q3 2025 | Aug 11, 2025 | $0.90vs $0.70-28.6% | — |
| Q2 2025 | May 12, 2025 | $1.90vs $0.66-187.9% | — |
Based on last 12 quarters of dataView full earnings history →
AVBP Peer Comparison
ArriVent BioPharma, Inc. Common Stock (AVBP) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 TARS | 2.76B | 64.76 | -40.73 | 146.71% | -9.02% | -14.19% | 0.27 | |
 ERAS | 3.09B | 10.90 | -15.80 | -36.7% | 0.12 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 |
Compare AVBP vs Peers
ArriVent BioPharma, Inc. Common Stock (AVBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVBP Income Statement
ArriVent BioPharma, Inc. Common Stock (AVBP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.7M▲ 0% | -36.91M▼ 324.4% | -74.59M▼ 102.1% | -94.31M▼ 26.4% | 0▲ 100.0% |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -324.4% | -102.11% | -26.44% | 100% |
| EBITDA | -51.61M | 0 | -74.59M | -80.49M | 0 |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | 100% | - | -7.91% | 100% |
| D&A (Non-Cash Add-back) | 0 | 36.91M | 0 | 0 | 0 |
| EBIT | -51.61M | -36.91M | -74.59M | -80.49M | 0 |
| Net Interest Income | 0 | 0 | 5.26M | 13.82M | 0 |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -42.91M | 0 | 5.26M | 13.82M | 0 |
| Pretax Income | -51.61M▲ 0% | -36.91M▲ 28.5% | -69.33M▼ 87.9% | -80.49M▼ 16.1% | -166.31M▼ 106.6% |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% |
| Net Income | -51.61M▲ 0% | -36.91M▲ 28.5% | -69.33M▼ 87.9% | -80.49M▼ 16.1% | -166.31M▼ 106.6% |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | 28.49% | -87.86% | -16.09% | -106.62% |
| Net Income (Continuing) | -51.61M | -36.91M | -69.33M | -80.49M | -166.31M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -40.44▲ 0% | -1.10▲ 97.3% | -2.17▼ 97.3% | -2.56▼ 18.0% | -4.32▼ 68.8% |
| EPS Growth % | - | 97.28% | -97.27% | -17.97% | -68.75% |
| EPS (Basic) | -40.44 | -1.10 | -2.17 | -2.56 | -4.32 |
| Diluted Shares Outstanding | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Basic Shares Outstanding | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Dividend Payout Ratio | - | - | - | - | - |
AVBP Balance Sheet
ArriVent BioPharma, Inc. Common Stock (AVBP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Total Current Assets | 42.95M | 182.62M | 159.97M | 226.98M | 332.9M |
| Cash & Short-Term Investments | 37.28M | 163.37M | 150.39M | 218.86M | 312.82M |
| Cash Only | 37.28M | 163.37M | 150.39M | 74.29M | 45.54M |
| Short-Term Investments | 0 | 0 | 0 | 144.57M | 267.28M |
| Accounts Receivable | 0 | 0 | 0 | 500K | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 5.64M | 18.92M | 9.21M | 0 | 20.08M |
| Total Non-Current Assets | 87K | 211K | 3.13M | 47.96M | 272K |
| Property, Plant & Equipment | 0 | 139K | 291K | 154K | 13K |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 47.68M | 0 |
| Other Non-Current Assets | 87K | 72K | 2.84M | 126K | 259K |
| Total Assets | 43.04M▲ 0% | 182.83M▲ 324.8% | 163.1M▼ 10.8% | 274.94M▲ 68.6% | 333.17M▲ 21.2% |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | 324.81% | -10.79% | 68.57% | 21.18% |
| Total Current Liabilities | 1.82M | 8.36M | 11.62M | 17.27M | 25.95M |
| Accounts Payable | 293K | 3.09M | 4.53M | 3.78M | 5.93M |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 14K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 4.16M | 25.93M |
| Current Ratio | 23.63x | 21.84x | 13.76x | 13.14x | 12.83x |
| Quick Ratio | 23.63x | 21.84x | 13.76x | 13.14x | 12.83x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 11K | 177K | 14K | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 11K | 177K | 14K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.82M | 8.37M | 11.8M | 17.29M | 25.95M |
| Total Debt | 0 | 139K | 317K | 176K | 14K |
| Net Debt | -37.28M | -163.23M | -150.07M | -74.12M | -45.53M |
| Debt / Equity | - | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - |
| Total Equity | 41.22M▲ 0% | 174.46M▲ 323.2% | 151.3M▼ 13.3% | 257.65M▲ 70.3% | 307.22M▲ 19.2% |
| Equity Growth % | - | 323.24% | -13.28% | 70.3% | 19.24% |
| Book Value per Share | 32.30 | 5.21 | 4.73 | 8.19 | 7.99 |
| Total Shareholders' Equity | 41.22M | 174.46M | 151.3M | 257.65M | 307.22M |
| Common Stock | 0 | 0 | 0 | 3K | 4K |
| Retained Earnings | -51.61M | -88.51M | -157.84M | -238.33M | -404.64M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2K | 0 | 0 | -211K | 14K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
AVBP Cash Flow Statement
ArriVent BioPharma, Inc. Common Stock (AVBP) cash flow — operating, investing & free cash flow history
| Line item | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|
| Cash from Operations | -12.59M | -43.63M | -55.84M | -70.21M | -160.59M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | -246.64% | -27.99% | -25.73% | -128.72% |
| Net Income | -51.61M | -36.91M | -69.33M | -80.49M | -166.31M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | -3.03M |
| Stock-Based Compensation | 0 | 424K | 895K | 3.21M | 12.52M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 42.96M | 0 | 0 | 0 | -3.77M |
| Working Capital Changes | -3.94M | -7.15M | 12.6M | 7.07M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 293K | 2.8M | 1.38M | -751K | 2.14M |
| Cash from Investing | -40M | 0 | 0 | -192.47M | -71.23M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | -40M | 0 | 0 | 0 | 0 |
| Cash from Financing | 89.87M | 169.72M | 42.86M | 186.58M | 203.06M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 15K | -2.06M | 631K | 203.06M |
| Net Change in Cash | 37.28M▲ 0% | 126.09M▲ 238.2% | -12.98M▼ 110.3% | -76.1M▼ 486.1% | -28.75M▲ 62.2% |
| Free Cash Flow | -12.59M▲ 0% | -43.63M▼ 246.6% | -55.84M▼ 28.0% | -70.21M▼ 25.7% | -160.59M▼ 128.7% |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | -246.64% | -27.99% | -25.73% | -128.72% |
| FCF per Share | -9.86 | -1.30 | -1.75 | -2.23 | -4.18 |
| FCF Conversion (FCF/Net Income) | 0.24x | 1.18x | 0.81x | 0.87x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
AVBP Key Ratios
ArriVent BioPharma, Inc. Common Stock (AVBP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -125.19% | -34.22% | -42.57% | -39.36% | -58.88% |
| Return on Invested Capital (ROIC) | - | -364.92% | -898.39% | -76.56% | - |
| Debt / Equity | - | 0.00x | 0.00x | 0.00x | 0.00x |
| FCF Conversion | 0.24x | 1.18x | 0.81x | 0.87x | 0.97x |
AVBP SEC Filings & Documents
ArriVent BioPharma, Inc. Common Stock (AVBP) SEC filings — annual & quarterly reports (10-K, 10-Q)
AVBP Frequently Asked Questions
ArriVent BioPharma, Inc. Common Stock (AVBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ArriVent BioPharma, Inc. Common Stock (AVBP) grew revenue by 0.0% over the past year. Growth has been modest.
ArriVent BioPharma, Inc. Common Stock (AVBP) reported a net loss of $166.3M for fiscal year 2025.
Dividend & Returns
ArriVent BioPharma, Inc. Common Stock (AVBP) has a return on equity (ROE) of -58.9%. Negative ROE indicates the company is unprofitable.
ArriVent BioPharma, Inc. Common Stock (AVBP) had negative free cash flow of $160.6M in fiscal year 2025, likely due to heavy capital investments.
Explore More AVBP
ArriVent BioPharma, Inc. Common Stock (AVBP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates